EPHX2 and Alzheimer disease: Indeed, based on the evidence to date, reductions in free proresolving oxylipins characterized in AD could not be attributed to their synthetic enzymes (12/15-LOX, 5-LOX, and sEH), as these enzymes were shown to increase (rather than decrease) in both rodent models of AD (23, 34) and in human AD postmortem brain (17, 18).